ClinicalTrials.gg
TerminatedNCT05956509Updated Jul 1, 2024

Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity

A Phase 1 interventional study of ABBV-950 and BOTOX in Upper Limb Spasticity, sponsored by AbbVie. Terminated at 9 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-07-01.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

Why this study was terminated
Strategic considerations

From the registry’s dates

  • Primary completion was Jun 2024, 2 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
1
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 58 studies testing botulinum toxin type A in Muscle Spasticity — 4 open to participants now, 4 under way, 1 of them phase 3. botulinum toxin type A · Muscle Spasticity.

Enrollment
56th of 58
1 · median 62
Started
2024
the only one that year
Phase 1
4 of 58
1 open now
Registered
54th of 58
by date
Lead sponsor
1 of 58
AbbVie

Among the 58 studies testing botulinum toxin type A in Muscle Spasticity, this one is the 56th largest by enrollment, is the only one that started in 2024, is one of 4 in phase 1, and was the 54th registered.

Muscle Spasticity

622 studies on the registry are indexed under Muscle Spasticity; 128 are open to participants now.

Browse Muscle Spasticity studies →

Open to participants now

4 of the 58 studies testing botulinum toxin type A in Muscle Spasticity are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About botulinum toxin type A

botulinum toxin type A: first FDA approval 1991 (BOTOX COSMETIC), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 88 Muscle Spasticity studies recruiting now, 29 (33%) set no upper age limit and 47 (53%) stop at 75 or younger; 34 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies testing botulinum toxin type A in Muscle Spasticity, or all of them as a file.
02

Study summary

Spasticity is often observed as muscle tightness and stiffness in the upper and/or lower limbs. Upper limb spasticity can interfere with joint movement and its severity can range from mild to severe. Common causes of spasticity include cerebral palsy, traumatic brain injury, multiple sclerosis, spinal cord injury, and stroke. This study will assess how safe and effective ABBV-950 is in treating upper limb spasticity in adult post-stroke participants. Adverse events and change in symptoms will be assessed.

ABBV-950 in an investigational drug being developed for treating spasticity. This study is conducted in 2 parts. In Part 1, participants are assigned to receive different doses of ABBV-950 or placebo. There is 1 in 4 chance that participants will be assigned to receive placebo. In Part 2, participants will be randomly assigned to receive BOTOX, ABBV-950, or placebo. There is 1 in 5 chance for participants to receive placebo. Approximately 297 adult post-stroke participants with upper limb spasticity will be enrolled at approximately 50 sites in the United States.

In Part 1, participants will receive intramuscular (IM) injections of ABBV-950 or placebo on Day 1. In Part 2, participants will receive IM injections of BOTOX, ABBV-950, or placebo on Day 1. All participants will be followed for 24 weeks.

There may be higher treatment burden for participants in this trial compared to the standard of care. Participants will attend regular clinic visits during the study. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.

03

Conditions studied

  • Upper Limb Spasticity

Keywords

  • Spasticity
  • Upper Limb Spasticity
  • Stroke
  • ABBV-950
  • Botulinum toxin type A
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of upper limb spasticity due to stroke, with most recent stroke occurring at least 12 weeks prior to the Screening visit.
  • Modified Ashworth Scale-Bohannon (MAS-B) score of >= 3 in the wrist flexors, and a score of >= 1+ in the finger flexors and MAS-B score of >= 2 elbow flexors at both Screening and Visit 2 (Baseline).

Exclusion criteria

Exclusion Criteria:

  • Additional strokes in the 12 weeks preceding the most recent stroke and in the opinion of the investigator, is not at significant risk of experiencing another stroke during the study period.
  • Spasticity in the contralateral upper limb that requires treatment.
  • Presence of fixed contractures in muscles of wrist, elbow, fingers.
  • Botulinum toxin treatment of any serotype in the 20 weeks prior to Day for upper limb spasticity and in the 12 weeks prior to Day 1 for any indication other than upper limb spasticity.
  • Previous surgical intervention, nerve block, or muscle block for the treatment of spasticity in the study limb in the last 12 months.
  • Injection of or anesthetics in the study limb within 12 weeks.
  • Casting of the upper limbs within 12 weeks.
  • Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, and/or amyotrophic lateral sclerosis.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    Part 1: ABBV-950 Dose A

    Participants will receive ABBV-Dose A on Day 1.

    Biological: ABBV-950

  • Placebo comparator
    Part 1: Placebo for ABBV-950 Dose A

    Participants will receive placebo for ABBV-950 on Day 1.

    Drug: Placebo for ABBV-950

  • Experimental
    Part 1: ABBV-950 Dose B

    Participants will receive ABBV-950 Dose B on Day 1.

    Biological: ABBV-950

  • Placebo comparator
    Part 1: Placebo for ABBV-950 Dose B

    Participants will receive placebo for ABBV-950 on Day 1.

    Drug: Placebo for ABBV-950

  • Experimental
    Part 1: ABBV-950 Dose C

    Participants will receive ABBV-950 Dose C on Day 1.

    Biological: ABBV-950

  • Placebo comparator
    Part 1: Placebo for ABBV-950 Dose C

    Participants will receive placebo for ABBV-950 on Day 1.

    Drug: Placebo for ABBV-950

  • Active comparator
    Part 2: BOTOX Dose A

    Participants will receive BOTOX Dose A on Day 1.

    Biological: BOTOX

  • Experimental
    Part 2: ABBV-950 Dose A

    Participants will receive ABBV-950 Dose A on Day 1.

    Biological: ABBV-950

  • Experimental
    Part 2: ABBV-950 Dose B

    Participants will receive ABBV-950 Dose B on Day 1.

    Biological: ABBV-950

  • Experimental
    Part 2: ABBV-950 Dose C

    Participants will receive ABBV-950 Dose C on Day 1.

    Biological: ABBV-950

  • Placebo comparator
    Part 2: Placebo for ABBV-950

    Participants will receive placebo for ABBV-950 on Day 1.

    Drug: Placebo for ABBV-950

Interventions

  • BiologicalABBV-950

    Intramuscular (IM) Injection

    Also known as: Botulinum toxin type A

  • BiologicalBOTOX

    Intramuscular (IM) Injection

    Also known as: OnabotulinumtoxinA

  • DrugPlacebo for ABBV-950

    Intramuscular (IM) Injection

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Wrist Modified Ashworth Scale-Bohannon (MAS-B)

    MAS-B measures muscle tone based on grading the resistance encountered in a specific muscle group by means of passively moving a limb through its range of motion at a study-specified velocity. Score ranges from 0 (No increase in muscle tone) through 4 (Affected part(s) rigid in flexion or extension).

    Time frame: Up to Week 6

  2. Number of Participants Experiencing Adverse Events

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.

    Time frame: Up to Week 24

Secondary outcomes

  1. Change in Clinician Global Impression of Change (CGI-C) Score

    CGI-C is a 9-point rating scale used to measure the clinician's impression of overall treatment response since the first dose of study intervention. CGI-C scores range from -4 = very marked worsening to +4 = very marked improvement.

    Time frame: Up to Week 6

  2. Change in Clinician Global Impression of Severity (CGI-S) Score

    CGI-S is a 5-point rating scale used to measure the clinician's or trained personnel's impression of the current severity of the participant's upper limb spasticity. Scores range from 0 = no spasticity to 4 = very severe.

    Time frame: Up to Week 6

  3. Percentage of Participants Achieving Wrist MAS-B Responder Status

    MAS-B measures muscle tone based on grading the resistance encountered in a specific muscle group by means of passively moving a limb through its range of motion at a study-specified velocity. Score ranges from 0 (No increase in muscle tone) through 4 (Affected part(s) rigid in flexion or extension). Responder is defined as participant with \>= 1 grade improvement from baseline.

    Time frame: Up to Week 6

07

Study locations

9 sites
  • North County Neurology Associates /ID# 256333
    Carlsbad, California 92011-4213, United States
  • Rancho Los Amigos National Rehabilitation center /ID# 255335
    Downey, California 90242, United States
  • Neuro Pain Medical Center /ID# 256036
    Fresno, California 93710-5473, United States
  • New England Institute for Clinical Research /ID# 255020
    Stamford, Connecticut 06905, United States
  • MedStar National Rehabilitation Hospital /ID# 255630
    Washington, District of Columbia 20010, United States
  • JEM Research Institute /ID# 258782
    Lake Worth, Florida 33462-1141, United States
  • Kansas Institute of Research /ID# 254998
    Overland Park, Kansas 66211-1363, United States
  • University of Missouri Hospital /ID# 255310
    Columbia, Missouri 65212, United States
  • Ut Southwestern Medical Center /Parkland Health and Hospital System /Id# 255328
    Dallas, Texas 75235-7709, United States
08

References and documents

Related links

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2024 to primary completion in Jun 2024, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2023
First posted
Jul 21, 2023
StartActual
Jan 12, 2024
Primary completionActual
Jun 2, 2024
CompletionActual
Jun 2, 2024
Last update
Jul 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05956509
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jul 21, 2023
Start date
Jan 12, 2024
Primary completion
Jun 2, 2024
Completion
Jun 2, 2024
Last update
Jul 1, 2024

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Botulinum toxin type A

Start the discussion